3'- O -β-d-glucopyranosyl-α,4,2',4',6'-pentahydroxy-dihydrochalcone, from Bark of Eysenhardtia polystachya Prevents Diabetic Nephropathy via Inhibiting Protein Glycation in STZ-Nicotinamide Induced Diabetic Mice

• Published in: Molecules (Basel, Switzerland) Switzerland), 2019-03, Vol.24 (7), p.1214
• Main Authors: Pérez Gutierrez, Rosa Martha, García Campoy, Abraham Heriberto, Paredes Carrera, Silvia Patricia, Muñiz Ramirez, Alethia, Mota Flores, José Maria, Flores Valle, Sergio Odin
• Format: Article
• Language: English
• Subjects: advanced glycation end-product; Advanced glycosylation end products; Animals; Attenuation; Bark; Biomarkers - metabolism; Body weight; Body Weight - drug effects; Chalcones - chemical synthesis; Chalcones - chemistry; Chalcones - pharmacology; Chalcones - therapeutic use; Creatinine; Creatinine - blood; Diabetes; Diabetes mellitus; Diabetes Mellitus, Experimental - blood; Diabetes Mellitus, Experimental - drug therapy; diabetic mice; Diabetic Nephropathies - blood; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - pathology; Diabetic nephropathy; dihydrochalcone; Drinking; Eysenhardtia polystachya; Fabaceae - chemistry; Feeding Behavior; Food; Glucose; Glucose - metabolism; Glycated Hemoglobin A - metabolism; Glycation End Products, Advanced - blood; Glycosylation; Hemoglobin; Hyperglycemia; Inflammation; Inflammation Mediators - metabolism; Intercellular adhesion molecule 1; Kidney - drug effects; Kidney - pathology; Kidneys; Male; Markers; Mice, Inbred C57BL; Nephropathy; Niacinamide; Nicotinamide; Nitrogen; Organ Size - drug effects; Oxidative stress; Plant Bark - chemistry; Proteins; Rats; Renal function; renoprotective; Streptozocin; Tissue analysis; Urea; Urea - blood; Uric acid; Uric Acid - blood; Urine
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules24071214

Previous studies have shown that accumulation of advanced glycation end products (AGEs) can be the cause of diabetic nephropathy (DN) in diabetic patients. Dihydrochalcone 3'- -β-d-glucopyranosyl α,4,2',4',6'-pentahydroxy⁻dihydrochalcone ( ) is a powerful antiglycation compound previously isolated from . The aim was to investigate whether ( ) was able to protect against diabetic nephropathy in streptozotocin (STZ)-induced diabetic mice, which displayed renal dysfunction markers such as body weight, creatinine, uric acid, serum urea, total urinary protein, and urea nitrogen in the blood (BUN). In addition, pathological changes were evaluated including glycated hemoglobin (HbA1c), advanced glycation end products (AGEs) in the kidney, as well as in circulation level and pro-inflammatory markers ICAM-1 levels in diabetic mice. After 5 weeks, these elevated markers of dihydrochalcone treatment (25, 50 and 100 mg/kg) were significantly ( < 0.05) attenuated. In addition, they ameliorate the indices of renal inflammation as indicated by ICAM-1 markers. The kidney and circulatory AGEs levels in diabetic mice were significantly ( < 0.05) attenuated by ( ) treatment. Histological analysis of kidney tissues showed an important recovery in its structure compared with the diabetic group. It was found that the compound ( ) attenuated the renal damage in diabetic mice by inhibiting AGEs formation.